Isotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Study

Simple item page
dc.coverageDOI: 10.1001/jamadermatol.2022.2044
dc.creatorXia, Eric
dc.creatorHan, Jane
dc.creatorFaletsky, Adam
dc.creatorBaldwin, Hilary
dc.creatorBeleznay, Katie
dc.creatorBettoli, Vincenzo
dc.creatorDréno, Brigitte
dc.creatorGoh, Chee Leok
dc.creatorStein Gold, Linda
dc.creatorGollnick, Harald
dc.creatorHerane, Maria Isabel
dc.creatorKang, Sewon
dc.creatorKircik, Leon
dc.creatorMann, Julianne
dc.creatorNast, Alexander
dc.creatorOon, Hazel H.
dc.creatorSee, Jo Ann
dc.creatorTollefson, Megha
dc.creatorWebster, Guy
dc.creatorZip, Catherine
dc.creatorTan, Jerry
dc.creatorTapper, Elliot B.
dc.creatorThiboutot, Diane
dc.creatorZaenglein, Andrea
dc.creatorBarbieri, John
dc.creatorMostaghimi, Arash
dc.date2022
dc.date.accessioned2026-01-05T21:09:04Z
dc.date.available2026-01-05T21:09:04Z
dc.description<p>Importance: Although isotretinoin may rarely be associated with laboratory abnormalities such as hypertriglyceridemia, the optimal approach to laboratory monitoring is uncertain, and there is wide variation in clinical practice. Objective: To establish a consensus for isotretinoin laboratory monitoring among a diverse, international cohort of clinical and research experts in acne. Design, Setting, and Participants: Using a modified electronic Delphi process, 4 rounds of anonymous electronic surveys were administered from 2021 to 2022. For laboratory tests reaching consensus (≥70% agreement) for inclusion, questions regarding more time-specific monitoring throughout isotretinoin therapy were asked in subsequent rounds. The participants were international board-certified dermatologist acne experts who were selected on a voluntary basis based on involvement in acne-related professional organizations and research. Main Outcomes and Measures: The primary outcome measured was whether participants could reach consensus on key isotretinoin laboratory monitoring parameters. Results: The 22 participants from 5 continents had a mean (SD) time in practice of 23.7 (11.6) years and represented a variety of practice settings. Throughout the 4-round study, participation rates ranged from 90% to 100%. Consensus was achieved for the following: check alanine aminotransferase within a month prior to initiation (89.5%) and at peak dose (89.5%) but not monthly (76.2%) or after treatment completion (73.7%); check triglycerides within a month prior to initiation (89.5%) and at peak dose (78.9%) but not monthly (84.2%) or after treatment completion (73.7%); do not check complete blood cell count or basic metabolic panel parameters at any point during isotretinoin treatment (all &gt;70%); do not check gamma-glutamyl transferase (78.9%), bilirubin (81.0%), albumin (72.7%), total protein (72.7%), low-density lipoprotein (73.7%), high-density lipoprotein (73.7%), or C-reactive protein (77.3%). Conclusions and Relevance: This Delphi study identified a core set of laboratory tests that should be evaluated prior to and during treatment with isotretinoin. These results provide valuable data to guide clinical practice and clinical guideline development to optimize laboratory monitoring in patients treated with isotretinoin.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/029a8ba8-3030-46c5-a0c2-f694c0356178
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/63679
dc.languageeng
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.sourcevol.158 (2022) nr.8 p.942-948
dc.titleIsotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Studyeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
Pure-CRIS